Male genital system lymphoma: Clinicopathological analysis of 80 cases.
- Author:
Xiao-Die ZHOU
1
;
Rong-Xin QI
2
;
Bo YU
1
;
Xuan WANG
1
;
Qun-Li SHI
1
;
Qiu RAO
1
;
Wei BAO
1
Author Information
1. Department of Pathology, General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China.
2. Department of Nuclear Medicine, General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- Keywords:
male reproductive system;
lymphoma;
clinicopathology;
prognosis
- MeSH:
Humans;
Male;
Middle Aged;
Aged;
Retrospective Studies;
Adult;
Aged, 80 and over;
Young Adult;
Adolescent;
Child;
Child, Preschool;
Genital Neoplasms, Male/diagnosis*;
Prognosis;
Lymphoma, Large B-Cell, Diffuse/diagnosis*;
Lymphoma/diagnosis*
- From:
National Journal of Andrology
2025;31(2):138-143
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinicopathological features and differential diagnosis of male genital system lymphoma (MGSL).
METHODS:We retrospectively analyzed the clinicopathological and immunophenotypic features and prognosis of 80 cases of MGSL.
RESULTS:The onset age of the MGSL patients ranged from 4 to 85 (median 62) years old. All the cases showed non-specificity of the imaging features and clinical manifestations. MGSL was located mainly in the testis (n = 66), followed by the prostate (n = 7), epididymis (n = 3), scrotum (n = 3) and penile glans (n = 1). Diffused large B cell lymphoma (DLBCL) was the most common pathological type (n = 62), next came extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) (n = 7) and other rare types (n = 12). During the 1－112-month follow-up of 10 of the 19 patients, 1 died at 1 month after diagnosed with prostatic B-lymphoblastic lymphoma (B-LBL) and another 1 died at 50 months after diagnosed with testicular DLBCL.
CONCLUSION:MGSL is rare clinically, mainly of the DLBCL type pathologically, lacking specificity in clinical symptoms and imaging manifestation. The definite diagnosis of the malignancy depends on histopathology combined with related molecular examination and immunohistochemical labeling, and R-CHOP chemotherapy is the first choice for its treatment.
